
Keywords: Claudin; Tight junction; Antibody therapy; Microenvironment; MIUC; muscle invasive urothelial cancers; CLDN; claudin; SPR; surface plasmon resonance; CDDP; cisplatinum; EGFR; epidermal growth factor receptor; ERK; extracellular signal-regulated kinase; EG